Acute Coronary Syndrome Clinical Trial
Official title:
Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study
In patients with heart attacks, the treatment of choice is to restore blood flow with
percutaneous coronary intervention (PCI) (use of stents (metal meshes) to open blockages).
After PCI, the standard drug treatment includes aspirin and clopidogrel. These medications
block full function of the platelet cells, which are responsible for clotting. Despite their
use, patients after PCI are at risk for heart attacks, sudden clotting of stents or death. A
major contributor may be resistance to clopidogrel. New more potent drugs, which can overcome
the resistance, are now available; however, they come with an increase chance of severe
bleeding and costs. An ideal solution would be to identify at-risk patients and selectively
treat them with more potent drugs, while lower-risk patients continue with clopidogrel. This
type of strategy (personalized strategy) would decrease heart attacks and death (compared to
clopidogrel), while also preventing bleeding complications (compared to treating all patients
with the new drugs).
Of resistant patients, many carry genes (inherited units) that prevent proper absorption of
clopidogrel. Our group has developed and tested a new bedside genetic test, which identifies
carriers of at-risk genes. However, this technique alone does not identify all at-risk
patients. Consequently, we have now devised a novel tool, which combines genetics with
patient characteristics to identify high-risk patients.
The present study combines this new tool into a strategy for personalized treatment. Patients
with heart attacks who undergo PCI will be randomly assigned to 1 of 3 strategies: a) new
personalized strategy, b) clopidogrel strategy (previous standard drug) or c) ticagrelor
strategy (stronger approved drug). The function of the platelet cells will be measured at 1
month to determine potential benefits. Evaluation of this new personalized strategy is
important for improving patient outcomes after PCI. The hypothesis is that patients receiving
a personalized strategy will have decrease risk for future heart attacks and bleeding.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
| Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
| Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
| Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
| Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
| Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
| Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
| Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
| Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
| Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
| Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
| Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
| Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
| Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
| Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
| Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
| Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
| Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
| Terminated |
NCT02620202 -
Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain
|